The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / 2014 ACR/ARHP Annual Meeting: Predicting Outcomes for Patients with Lupus Nephritis

2014 ACR/ARHP Annual Meeting: Predicting Outcomes for Patients with Lupus Nephritis

January 1, 2015 • By Mary Beth Nierengarten

  • Tweet
  • Email
Print-Friendly Version / Save PDF

In Situ Adaptive Immunity

You Might Also Like
  • 2014 ACR/ARHP Annual Meeting: Lupus Nephritis
  • 2014 ACR/ARHP Annual Meeting: Patient-Centered Outcomes Research Gaining Support
  • 2015 ACR/ARHP Annual Meeting: Latest Clinical Literature Offers New Strategies in Lupus Nephritis
Explore This Issue
January 2015
Also By This Author
  • Studies Highlight Risk of Damage from Lupus Treatments
Dr. Clark
Dr. Clark

Marcus Clark, MD, chief, Section of Rheumatology, Gwen Knapp Center for Lupus and Immunology Research, the University of Chicago, spoke on in situ adaptive immunity in LN. Among the key points of his talk was the prognostic importance of tubulointerstitial inflammation at the time of biopsy, which is a better indicator than glomerular inflammation in predicting the risk of progression to renal failure, with increased risk of progression to renal failure in patients with moderate to severe tubulointerstitial inflammation.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Severe tubulointerstitial inflammation, he said, is associated with B cell selection in situ mediated by T-follicular helper cells, and the antibodies selected in situ often react with a molecule called vimentin, which is highly expressed in inflammatory infiltrates.

“High-titer serum antibodies to vimentin in the serum appear to be a specific biomarker of severe tubulointerstitial disease,” he said. “This would be the first biomarker in blood for a specific histologic manifestation of LN of such prognostic importance.”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

TWEAK

Dr. Putterman
Dr. Putterman

Chaim Putterman, MD, chief, Division of Rheumatology, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, N.Y., spoke on the TNF-related weak inducer of apoptosis (TWEAK) molecule as a potential therapeutic target and biomarker for active LN. He presented data from a number of studies that show that the TNF-family member cytokine TWEAK, acting through the fibroblast growth factor-inducible 14 (Fn14), promotes inflammatory diseases by activating key cell types that drive pathology locally rather than by modifying adaptive immune responses.

He also highlighted data showing that inhibition of TWEAK signaling is effective in several experimental models of immune-mediated renal disease, including chronic graft-vs.-host (cGVH) disease, nephrotoxic serum nephritis and spontaneous LN in mice (i.e., MRL-lpr/lpr mouse strain).

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Data show as well that TWEAK is up-regulated in kidneys of mice and patients with active LN and can be found in the urine of lupus patients with active nephritis. Although he said this does not necessarily mean that TWEAK is pathogenic or directly injurious to the kidney, the presence of TWEAK in the urine of individuals with active LN “suggest a possible role of urinary TWEAK as a biomarker either used alone or maybe as a part of a larger panel of molecules that are up-regulated during nephritis but that wouldn’t be up-regulated in kidneys without active inflammation or in kidneys with nephritis, but not from lupus.”

Based on these and other studies, Dr. Putterman said that a large, multinational, Phase II clinical trial called ATLAS is currently enrolling patients to formally look at the role of an anti-TWEAK antibody as an add-on to the standard of care for patients with LN (see https://clinicaltrials.gov/ct2/show/NCT01499355?term=ATLAS+and+lupus&rank=1).

Pages: 1 2 3 | Single Page

Filed Under: Conditions, Meeting Reports, SLE (Lupus) Tagged With: 2014 ACR/ARHP Annual Meeting, Biomarkers, Lupus, Nierengarten, patient care, Research, rheumatologyIssue: January 2015

You Might Also Like:
  • 2014 ACR/ARHP Annual Meeting: Lupus Nephritis
  • 2014 ACR/ARHP Annual Meeting: Patient-Centered Outcomes Research Gaining Support
  • 2015 ACR/ARHP Annual Meeting: Latest Clinical Literature Offers New Strategies in Lupus Nephritis
  • 2014 ACR/ARHP Annual Meeting: Methotrexate Use in Patients with RA

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.